Skip to Content
Upcoming Webinar

Optimizing DLBCL Patient Outcomes with clonoSEQ MRD Monitoring

Date: September 29, 2025 | 2:00 PM
When: Monday, September 29 | 2 p.m. EST

For patients with DLBCL, minimal residual disease (MRD) testing can mean more than just numbers on a report — it can help guide therapy choices, inform surveillance, and give patients clarity about what comes next.

In this session, Tara Graff, DO, MS (Mission Cancer + Blood) and Jay Patel, PharmD, BCOP (Adaptive Biotechnologies) will share how MRD monitoring fits into real-world care: when to use it, how to interpret results, and how to talk about them with patients in a way that builds trust and understanding.

What You’ll Learn:

  • A clear view of why MRD monitoring matters in DLBCL
  • Practical examples of how to use clonoSEQ to track therapy response and long-term outcomes
  • Communication strategies that help patients feel supported, not overwhelmed, by their results

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.